MedTrace Logo

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

NCT00928525 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-10-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived growth factor (PDGF) both in its isoform alpha and beta

Conditions

  • Advanced Desmoid Tumor
  • Advanced Chondrosarcoma

Interventions

DRUG

Imatinib Mesylate

800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months

Sponsors & Collaborators

  • Italian Sarcoma Group

    lead NETWORK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928525 on ClinicalTrials.gov